Forskolin-stimulated platelet adenylyl cyclase activity is lower in persons with major depression

Biological Psychiatry

Volumn 42, Issue 1, 1997, Pages 30-38

  Menninger, John A ^a   Tabakoff, Boris ^a,b  

^a UNIVERSITY OF COLORADO   (United States)

^b Campus Box C 236 ^*  (United States)

Author keywords

Adenylyl cyclase; Forskolin; G proteins; Major depression; Platelets

Indexed keywords

ADENYLATE CYCLASE; ANTIDEPRESSANT AGENT; CESIUM; FLUORIDE ION; FORSKOLIN; GUANINE NUCLEOTIDE; GUANYLYLIMIDODIPHOSPHATE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL PROTOCOL; CONTROLLED STUDY; DEPRESSION; ENZYME ACTIVATION; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN CELL; MALE; PRIORITY JOURNAL; THROMBOCYTE;

ADENYLATE CYCLASE; ADULT; BLOOD PLATELETS; DEPRESSIVE DISORDER; ENZYME ACTIVATION; FEMALE; FORSKOLIN; HUMANS; MALE; MIDDLE AGED; REFERENCE VALUES; SEX FACTORS;

EID: 0030739982     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-3223(96)00245-4     Document Type: Article

References (60)

1. Abou-Saleh MT, Collins J, George A, Rommelspacher H (1994): Adrenoceptor activity and adenylate cyclase inhibition in depression [letter]. Br J Psychiatry 165:276-277.
2. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J (1961): An inventory for measuring depression. Arch Gen Psychiatry 4:561-571.
3. Birnbaumer L, Abramowitz J, Brown AM (1990): Receptor-effector coupling by G proteins. Biochim Biophys Acta 1031:163-224.
4. Brass LF, Manning DR, Shattil SJ (1991): GTP-binding proteins and platelet activation. Prog Hemost Thromb 10:127-174.
5. Bucholz KK, Cadoret R, Cloninger CR, et al (1994): A new, semi-structured psychiatric interview for use in genetic linkage studies: a report on the reliability of the SSAGA. J Stud Alcohol 55:149-158.
6. 2+ and calmodulin on adenylyl cyclase activity in plasma membranes derived from neural and non-neural cells. Cell Calcium 13:107-121.
7. 2+/calmodulin-stimulated enzyme expressed in discrete regions of rat brain. J Biol Chem 269:12190-12195.
8. Chen J, DeVivo M, Dingus J, et al (1995): A region of adenylyl cyclase 2 critical for regulation by G protein beta gamma subunits. Science 268:1166-1169.
9. Chen J, Rasenick MM (1995): Chronic antidepressant treatment facilitates G protein activation of adenylyl cyclase without altering G protein content. J Pharmacol Exp Ther 275:509-517.
10. Collins GG, Sandier M (1971): Human blood platelet monoamine oxidase. Biochem Pharmacol 20:289-296.
11. Cowburn RF, Marcusson JO, Eriksson A, Wiehager B, O'Neill C (1994): Adenylyl cyclase activity and G-protein subunit levels in postmortem frontal cortex of suicide victims. Brain Res 633:297-304.
12. Craven JL, Rodin GM, Littlefield C (1988): The Beck Depression Inventory as a screening device for major depression in renal dialysis patients. Int J Psychiatry Med 18:365-374.
13. Davis LC, Radke GA (1987): Measurement of protein using flow injection analysis with bicinchoninic acid. Anal Biochem 161:152-156.
14. Garcia-Sevilla JA, Padro D, Giralt MT, Guimon J, Areso P (1990): Alpha 2-adrenoceptor-mediated inhibition of platelet adenylyl cyclase and induction of aggregation in major depression. Effect of long-term cyclic antidepressant drug treatment. Arch Gen Psychiatry 47:125-132.
15. Grant BF, Hartford TC (1995): Comorbidity between DSM-IV alcohol use disorders and major depression: Results of a national survey. Drug Alcohol Depend 39:197-206.
16. Grant BF, Hartford TC, Dawson DA, Chou PS, Pickering RP (1995): The alcohol use disorder and associated disabilities interview schedule (AUDADIS): Reliability of alcohol and drug modules in a general population sample. Drug Alcohol Depend 39:37-44.
17. Hall RC, Wise MG (1995): The clinical and financial burden of mood disorders. Cost and outcome. Psychosomatics 36:S11-18.
18. Hellevuo K, Yoshimura M, Kao M, Hoffman PL, Cooper DM, Tabakoff B (1993): A novel adenylyl cyclase sequence cloned from the human erythroleukemia cell line. Biochem Biophys Res Commun 192:311-318.
19. Hellevuo K, Yoshimura M, Mons N, Hoffman PL, Cooper DM, Tabakoff B (1995): The characterization of a novel human adenylyl cyclase which is present in brain and other tissues. J Biol Chem 270:11581-11589.
20. Hudson TH, Fain JN (1983): Forskolin-activated adenylyl cyclase. Inhibition by guanyl-5′-yl imidodiphosphate. J Biol Chem 258:9755-9761.
21. Iyengar R (1993): Molecular and functional diversity of mammalian Gs-stimulated adenylyl cyclases. FASEB J 7:768-775.
22. Kafka MS, Nurnberger JI, Siever L, Targum S, Uhde TW, Gershon ES (1986): Alpha 2-adrenergic receptor function in patients with unipolar and bipolar affective disorders. J Affect Disord 10:163-169.
23. Kafka MS, Siever LJ, Nurnberger JI, et al (1985): Platelet alpha-adrenergic receptor function in affective disorders and schizophrenia. Psychopharmacol Bull 21:599-602.
24. Kanof PD, Johns CA, Davidson M, Siever LJ, Coccaro EF, Davis KL (1988): Platelet alpha 2-adrenergic receptor function in psychiatric disorders. Psychiatry Res 23:11-22.
25. Karege F, Bovier P, Widmer J, Gaillard JM, Tissot R (1992): Decrease in epinephrine-induced attenuation of platelet adenylate cyclase activity in depressed patients: relation with plasma electrolytes. Neuropsychobiology 26:129-135.
26. Katon W, Schulberg H (1992): Epidemiology of depression in primary care. Gen Hosp Psychiatry 14:237-247.
27. Keller MB, Hanks DL (1994): The natural history and heterogeneity of depressive disorders: implications for rational antidepressant therapy. J Clin Psychiatry 55:25-31; discussion 32-33, 98-100.
28. Lenox RH, Ellis JE, Van Riper DV, et al (1983): Platelet alpha2-adrenergic receptor activity in clinical studies of depression. In Usdin E, Goldstein M, Friedhoff AJ, Georgotas A (eds), Frontiers in Neuropsychiatric Research. London: MacMillan Press, pp 331-356.
29. Lingjaerde O (1990): Blood platelets as a model system for studying serotonergic dysfunction and effects of antidepressants. Pharmacol Toxicol 66(suppl 3):61-68.
30. Menkes DB, Rasenick MM, Wheeler MA, Bitensky MW (1983): Guanosine triphosphate activation of brain adenylate cyclase: enhancement by long-term antidepressant treatment. Science 219:65-67.
31. Mitrius JC, Micuni M, Arora RC, Meltzer HY, U'Prichard DC (1983): Responsiveness of alpha 2-adrenergic receptors s decreased in platelets from depressed patients. Soc Neuroscience Abstracts 9:990.
32. Mooney JJ, Schatzberg AF, Cole JO, Kizuka PP, Schildkraut JJ (1985): Enhanced signal transduction by adenylate cyclase in platelet membranes of patients showing antidepressant responses to alprazolam: preliminary data. J Psychiatr Res 19:65-75.
33. Motulsky HJ, Insel PA (1983): Influence of sodium on the alpha 2-adrenergic receptor system of human platelets. Role for intraplatelet sodium in receptor binding. J Biol Chem 258: 3913-3919.
34. Murphy DL, Donnelly C, Moskowitz J (1974): Catecholamine receptor function in depressed patients. Am J Psychiatry 131:1389-1391.
35. Nelson CA, Seamon KB (1986): Binding of [3H]forskolin to human platelet membranes. Regulation by guanyl-5′-yl imidodiphosphate, NaF, and prostaglandins E1 and D2. J Biol Chem 261:13469-13473.
36. Newman ME, Lerer B (1989): Modulation of second messenger function in rat brain by in vivo alteration of receptor sensitivity: relevance to the mechanism of action of electroconvulsive therapy and antidepressants. Prog Neuro-Psychopharmacol Biol Psychiatry 13:1-30.
37. Newman ME, Lerer B, Lichtenberg P, Shapira B (1992): Platelet adenylate cyclase activity in depression and after clomipramine and lithium treatment: relation to serotonergic function. Psychopharmacology 109:231-234.
38. Ozawa H, Gsell W, Frolich L, et al (1993): Imbalance of the Gs and Gi/o function in post-mortem human brain of depressed patients. J Neural Transm Gen Sect 94:63-69.
39. Ozawa H, Rasenick MM (1989): Coupling of the stimulatory GTP-binding protein Gs to rat synaptic membrane adenylate cyclase is enhanced subsequent to chronic antidepressant treatment. Mol Pharmacol 36:803-808.
40. Ozawa H, Rasenick MM (1991): Chronic electroconvulsive treatment augments coupling of the GTP-binding protein Gs to the catalytic moiety of adenylyl cyclase in a manner similar to that seen with chronic antidepressant drugs. J Neurochem 56:330-338.
41. Paterson JM, Smith SM, Harmar AJ, Antoni FA (1995): Control of a novel adenylyl cyclase by calcineurin. Biochem Biophys Res Commun 214:1000-1008.
42. Regier DA, Boyd JH, Burke JD, Jr., et al (1988): One-month prevalence of mental disorders in the United States. Based on five Epidemiologic Catchment Area sites. Arch Gen Psychiatry 45:977-986.
43. Roy A, Kafka MS (1989): Platelet adrenoceptors and prostaglandin responses in depressed patients. Psychiatry Res 30:181-189.
44. Salomon Y, Londos C, Rodbell M (1974): A highly sensitive adenylate cyclase assay. Anal Biochem 58:541-588.
45. Schildkraut JJ (1965): The catecholamine hypothesis of affective disorders: A review of supporting evidence. Am J Psychiatry 122:509-522.
46. Schuckit MA, Hesselbrock V, Tipp J, Anthenelli R, Bucholz K, Radziminski S (1994): A comparison of DSM-III-R, DSM-IV and ICD-10 substance use disorders diagnoses in 1922 men and women subjects in the COGA study. Collaborative Study on the Genetics of Alcoholism. Addiction 89:1629-1638.
47. Seamon K, Daly JW (1981): Activation of adenylate cyclase by the diterpene forskolin does not require the guanine nucleotide regulatory protein. J Biol Chem 256:9799-9801.
48. Seamon KB, Padgett W, Daly JW (1981): Forskolin: unique diterpene activator of adenylate cyclase in membranes and in intact cells. Proc Natl Acad Sci U S A 78:3363-3367.
49. Siever LJ, Kafka MS, Insel TR, Lake CR, Murphy DL (1983): Effect of long-term clorgyline administration on human platelet alpha-adrenergic receptor binding and platelet cyclic AMP responses. Psychiatry Res 9:37-44.
50. Siever LJ, Kafka MS, Targum S, Lake CR (1984): Platelet alpha-adrenergic binding and biochemical responsiveness in depressed patients and controls. Psychiatry Res 11:287-302.
51. Simmoteit R, Schulzki HD, Palm D, Mollner S, Pfeuffer T (1991): Chemical and functional analysis of components of adenylyl cyclase from human platelets treated with phorbolesters. FEBS Lett 285:99-103.
52. Sondek J, Lambright DG, Noel JP, Hamm HE, Sigler PB (1994): GTPase mechanism of G proteins from the 1.7-A crystal structure of transducin alpha-GDP-A1F-4. Nature 372:276-279.
53. Stahl SM (1985): Platelets as pharmacologic models for the receptors and biochemistry of monaminergic neurons. In Longenecker GL (ed), The Platelets: Physiology and Pharmacology. Orlando, FL: Academic Press, Inc., pp 307-340.
54. Steer ML, Wood A (1981): Inhibitory effects of sodium and other monovalent cations on human platelet adenylate cyclase. J Biol Chem 256:9990-9993.
55. Tang WJ, Iniguez-Lluhi JA, Mumby S, Gilman AG (1992): Regulation of mammalian adenylyl cyclases by G-protein alpha and beta gamma subunits. Cold Spring Harb Symp Quant Biol 57:135-144.
56. Wadman IA, Farndale RW, Martin BR (1991): Evidence for regulation of human platelet adenylate cyclase by phosphorylation. Inhibition by ATP and guanosine 5′-[beta-thio]-diphosphate occur by distinct mechanisms. Biochem J 276: 621-630.
57. Walker JM (1994): The bicinchoninic acid (BCA) assay for protein quantitation. Methods Mol Biol 32:5-8.
58. Wang YC, Pandey GN, Mendels J, Frazer A (1974): Platelet adenylate cyclase responses in depression: implications for a receptor defect. Psychopharmacologia 36:291-300.
59. Yamaoka K, Nanba T, Nomura S (1988): Direct influence of antidepressants on GTP binding protein of adenylate cyclase in cell membranes of the cerebral cortex of rats. J Neural Transm 71:165-175.
60. Yoshimura M, Ikeda H, Tabakoff B (1996): Mu opioid receptors inhibit dopamine-stimulated activity of type V adenylyl cyclase but enhance the dopamine-stimulated activity of type VII adenylyl cyclase. Mol Pharmacol 50:43-51.